<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606306</url>
  </required_header>
  <id_info>
    <org_study_id>AsthmaNet 004</org_study_id>
    <secondary_id>1U10HL098115</secondary_id>
    <nct_id>NCT01606306</nct_id>
  </id_info>
  <brief_title>Individualized Therapy For Asthma in Toddlers</brief_title>
  <acronym>INFANT</acronym>
  <official_title>Individualized Therapy For Asthma in Toddlers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The INFANT study will test whether, in preschool children 12-59 months of age with persistent
      asthma, the following Step 2 asthma therapies will provide similar degrees of asthma control:

        1. Daily inhaled corticosteroid (ICS) treatment,

        2. Daily leukotriene receptor antagonist (LTRA) treatment, and

        3. As-needed ICS plus short-acting beta agonist (as-needed ICS/SABA) rescue treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INFANT is a double-blind, randomized clinical trial in which all participants will receive
      each of the three therapies for 16 weeks by means of a cross-over study design. INFANT aims
      to determine whether individual children respond better to one treatment than another and, if
      so, whether those children can be identified by phenotypic characteristics or selected
      biomarkers. In this regard the INFANT study is expected to address critical gaps in current
      asthma management guidelines. Ultimately, the findings from this study are expected to help
      clarify treatment modalities for this population of young preschool children who are
      extremely difficult to treat.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations and Asthma Control Days.</measure>
    <time_frame>The last 14 weeks of each 16-week treatment period</time_frame>
    <description>The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthcare visits. Children were defined as differential responders if, first, the time to an asthma exacerbation was at least four weeks longer, or second, if the number of annualized ACDs was at least 31 days more for one treatment than another, in that order. If neither threshold was met, the participant was considered a non differential responder. Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Asthma</condition>
  <condition>Wheezing</condition>
  <arm_group>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crossover sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>daily fluticasone propionate</intervention_name>
    <description>Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>as-needed fluticasone propionate</intervention_name>
    <description>Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms</description>
    <arm_group_label>Crossover sequence 1</arm_group_label>
    <arm_group_label>Crossover sequence 2</arm_group_label>
    <arm_group_label>Crossover sequence 3</arm_group_label>
    <arm_group_label>Crossover sequence 4</arm_group_label>
    <arm_group_label>Crossover sequence 5</arm_group_label>
    <arm_group_label>Crossover sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  12-59 months of age.

          -  If the child is not currently taking long-term asthma controller therapy (meaning that
             the child has taken no inhaled corticosteroid or leukotriene receptor antagonist
             medication whatsoever over the past 6 months), then one of the following criteria must
             be met:

               -  Daytime asthma symptoms more than two days per week (average over the past 4
                  weeks),

               -  At least one nighttime awakening from asthma (over the past 4 weeks),

               -  Two or more asthma exacerbations requiring systemic corticosteroids in the
                  previous 6 months,

               -  Four or more wheezing episodes in the previous 12 months.

          -  If the child is currently taking long-term asthma controller therapy (meaning that the
             child has taken daily or intermittent/as-needed inhaled corticosteroid or leukotriene
             receptor antagonist over the past 6 months), then one of the following criteria must
             be met:

               -  Taking inhaled corticosteroid or leukotriene receptor antagonist for more than 3
                  months (or more than 90 days) out of the previous 6 months (or 180 days),

               -  Daytime asthma symptoms more than two days per week (average over the past 4
                  weeks),

               -  More than one nighttime awakening from asthma (over the past 4 weeks),

               -  Two or more asthma exacerbations requiring systemic corticosteroids in the
                  previous 12 months,

               -  Four or more wheezing episodes in the previous 12 months.

          -  Up to date with immunizations, including varicella (unless the subject has already had
             clinical varicella).

          -  Willingness to provide informed consent by the child's parent or guardian.

        Exclusion Criteria:

          -  Allergic reaction to the study medications or any component of the study drugs,
             including (but not limited to) urticaria, rash, angioedema, or hypotension following
             delivery,

          -  Chronic medical disorders that could interfere with drug metabolism/excretion (for
             instance chronic hepatic, biliary, or renal disease),

          -  Chronic medical disorders that may increase the risk of drug-related injury, including
             (but not limited to):

               -  Osteogenesis imperfecta (increased risk of bone demineralization/fracture with
                  corticosteroid therapy),

               -  Crohn's disease, ulcerative colitis, juvenile rheumatoid arthritis, clotting
                  disorders, or Factor deficiency (increased risk of bleeding with corticosteroid
                  therapy),

               -  G6PD deficiency (increased risk of hemolytic anemia with acetaminophen use),

               -  Phenylketonuria (potential for aspartame exposure with study interventions),

               -  Seizure disorder treated with anticonvulsants (risk of acetaminophen toxicity
                  with carbamazepine), or

               -  History of clotting disorders or Factor deficiency (increased risk of bleeding
                  with corticosteroids),

          -  Co-morbid disorders associated with wheezing including (but not limited to) immune
             deficiency disorders, cystic fibrosis, aspiration, clinically-relevant
             gastroesophageal reflux, tracheomalacia, congenital airway anomalies (clefts,
             fistulas, slings, rings), bronchiectasis, bronchopulmonary dysplasia, and/or history
             of premature birth before 35 weeks gestation,

          -  Significant developmental delay/failure to thrive, defined as 5th percentile for
             height and/or weight or crossing of two major percentile lines during the last year
             for age and sex,

          -  History of a near-fatal asthma exacerbation requiring intubation or assisted
             ventilation,

          -  No primary medical caregiver (e.g., a nurse practitioner, physician assistant,
             physician, or group medical practice such as a hospital-based clinic) whom the subject
             can contact for primary medical care,

          -  Three or more hospitalizations in the previous 12 months for wheezing or respiratory
             illnesses,

          -  Treatment with 5 or more courses of systemic corticosteroids (oral, intramuscular or
             intravenous) in the past 6 months,

          -  Current use of higher than step 2 NAEPP asthma guideline therapy

          -  If receiving allergy shots, change in the dose within the past 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William B Busse, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona College of Medicine</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center/Stroger Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <results_first_submitted>September 15, 2016</results_first_submitted>
  <results_first_submitted_qc>January 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2017</results_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Principal Investigator, AsthmaNet Data Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Wheezing</keyword>
  <keyword>Fluticasone</keyword>
  <keyword>Montelukast</keyword>
  <keyword>Preschool-age</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Respiratory Sounds</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Crossover Sequence 1</title>
          <description>daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate</description>
        </group>
        <group group_id="P2">
          <title>Crossover Sequence 2</title>
          <description>daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast</description>
        </group>
        <group group_id="P3">
          <title>Crossover Sequence 3</title>
          <description>daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate</description>
        </group>
        <group group_id="P4">
          <title>Crossover Sequence 4</title>
          <description>daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate</description>
        </group>
        <group group_id="P5">
          <title>Crossover Sequence 5</title>
          <description>as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast</description>
        </group>
        <group group_id="P6">
          <title>Crossover Sequence 6</title>
          <description>as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed First Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="47"/>
                <participants group_id="P4" count="45"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Second Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="43"/>
                <participants group_id="P4" count="44"/>
                <participants group_id="P5" count="46"/>
                <participants group_id="P6" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Third Treatment Period</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="41"/>
                <participants group_id="P6" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Crossover Sequence 1</title>
          <description>daily fluticasone propionate, followed by daily montelukast, followed by as needed fluticasone propionate</description>
        </group>
        <group group_id="B2">
          <title>Crossover Sequence 2</title>
          <description>daily fluticasone propionate, followed by as needed fluticasone propionate, followed by daily montelukast</description>
        </group>
        <group group_id="B3">
          <title>Crossover Sequence 3</title>
          <description>daily montelukast, followed by as needed fluticasone propionate, followed by daily fluticasone propionate</description>
        </group>
        <group group_id="B4">
          <title>Crossover Sequence 4</title>
          <description>daily montelukast, followed by daily fluticasone propionate, followed by as needed fluticasone propionate</description>
        </group>
        <group group_id="B5">
          <title>Crossover Sequence 5</title>
          <description>as needed fluticasone propionate, followed by daily fluticasone propionate, followed by daily montelukast</description>
        </group>
        <group group_id="B6">
          <title>Crossover Sequence 6</title>
          <description>as needed fluticasone propionate, followed by daily montelukast, followed by daily fluticasone propionate</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="49"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="52"/>
            <count group_id="B6" value="47"/>
            <count group_id="B7" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="13.6"/>
                    <measurement group_id="B2" value="40.7" spread="12.4"/>
                    <measurement group_id="B3" value="38.7" spread="11.6"/>
                    <measurement group_id="B4" value="38.6" spread="15.1"/>
                    <measurement group_id="B5" value="41.7" spread="12.7"/>
                    <measurement group_id="B6" value="41.2" spread="14.0"/>
                    <measurement group_id="B7" value="39.9" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="40"/>
                    <measurement group_id="B6" value="37"/>
                    <measurement group_id="B7" value="228"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parental Asthma</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="17"/>
                    <measurement group_id="B6" value="24"/>
                    <measurement group_id="B7" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systemic corticosteroids in past 12 monts</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not used</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hospitalized in past 12 months</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hospitalized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not hospitalized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="39"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Allergen Test</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eczema</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood eosinophils</title>
          <units>number of cells per micro-liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183" lower_limit="111" upper_limit="435"/>
                    <measurement group_id="B2" value="234" lower_limit="153" upper_limit="572"/>
                    <measurement group_id="B3" value="258" lower_limit="133" upper_limit="460"/>
                    <measurement group_id="B4" value="255" lower_limit="175" upper_limit="457"/>
                    <measurement group_id="B5" value="308" lower_limit="184" upper_limit="496"/>
                    <measurement group_id="B6" value="310" lower_limit="182" upper_limit="536"/>
                    <measurement group_id="B7" value="258" lower_limit="158" upper_limit="492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum IgE</title>
          <units>international units per liter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" lower_limit="25" upper_limit="212"/>
                    <measurement group_id="B2" value="106.5" lower_limit="22" upper_limit="463"/>
                    <measurement group_id="B3" value="64" lower_limit="21" upper_limit="141"/>
                    <measurement group_id="B4" value="64" lower_limit="31" upper_limit="143"/>
                    <measurement group_id="B5" value="87" lower_limit="19" upper_limit="237"/>
                    <measurement group_id="B6" value="84" lower_limit="19" upper_limit="348"/>
                    <measurement group_id="B7" value="70" lower_limit="22" upper_limit="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations and Asthma Control Days.</title>
        <description>The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthcare visits. Children were defined as differential responders if, first, the time to an asthma exacerbation was at least four weeks longer, or second, if the number of annualized ACDs was at least 31 days more for one treatment than another, in that order. If neither threshold was met, the participant was considered a non differential responder. Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period.</description>
        <time_frame>The last 14 weeks of each 16-week treatment period</time_frame>
        <population>Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period.</population>
        <group_list>
          <group group_id="O1">
            <title>All Evaluable Participants</title>
            <description>Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period. Because placebo washouts were not performed, the data collected during the first two weeks of each period were not included in the analysis of ACDs. Days with missing diary data were also excluded from ACD determination.</description>
          </group>
        </group_list>
        <measure>
          <title>Differential Response to the Three Therapies Based on Fixed Threshold Criteria for the Following Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations and Asthma Control Days.</title>
          <description>The primary outcome was differential response to the three therapies on the basis of fixed threshold criteria for the following asthma control measures, which encompassed domains of risk and impairment: the time from the start of the treatment period to an asthma exacerbation treated with systemic corticosteroids, and the annualized number of asthma control days (ACDs) from within that period. ACDs were defined as full calendar days without symptoms, rescue medication use, or unscheduled healthcare visits. Children were defined as differential responders if, first, the time to an asthma exacerbation was at least four weeks longer, or second, if the number of annualized ACDs was at least 31 days more for one treatment than another, in that order. If neither threshold was met, the participant was considered a non differential responder. Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period.</description>
          <population>Differential response was determined in children completing at least two treatment periods and at least 50% of the daily diary entries for each period.</population>
          <units>probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-differential responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".26" lower_limit=".26" upper_limit=".26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responded best to daily ICS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".40" lower_limit=".33" upper_limit=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responded best to daily LTRA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".18" lower_limit=".13" upper_limit=".23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responded best to as-needed ICS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".16" lower_limit=".11" upper_limit=".21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The primary analysis tested the null hypothesis of all three treatments having equal probability to yield the best response as defined by the criteria defining the primary outcome. A sample size of 300 participants was selected to test the primary null hypothesis of all three treatments having equal probability (one-third) to yield the best response with statistical power of at least 0.90 if any one of the three treatments actually has probability of at least one-half to yield the best response.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Rank-ordered logistic regression (ROLR) was used to model the probability of best response for each treatment and bootstrapping was used to calculate confidence intervals.</p_value_desc>
            <method>rank-order logistic regression</method>
            <method_desc>ROLR is in the class of Discrete Choice models, which seek to estimate the probability that an individual responds best to a specific treatments.</method_desc>
            <other_analysis_desc>The probabilistic construct of the Discrete Choice (DC) model does not reflect individual behavior that is intrinsically probabilistic, but rather population heterogeneity. DC models rely on stochastic assumptions to account for unobserved factors related to the treatments themselves and to characteristics of study participants. Specifically, that each treatment has an underlying utility that may differ from one individual to another. Mathematically, these utilities are represented by U_t, where t denotes the treatment. Utility can be thought of as a latent variable quantifying treatment response where higher values indicate better response. The U_t can be used to find the probability (P) of best response for each treatment by the following equation: P_t = exp(U_t) / [exp(U_A) + exp(U_B) + exp(U_C)], where A, B, and C, denote the three study treatments. The primary analysis tested whether the three treatments have equal utility and, thus, equal probability of best response.</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Daily ICS</title>
          <description>Daily inhaled corticosteroid (ICS) treatment</description>
        </group>
        <group group_id="E2">
          <title>As-needed ICS</title>
          <description>As-needed ICS plus short-acting beta agonist (as-needed ICS/SABA) rescue treatment.</description>
        </group>
        <group group_id="E3">
          <title>Daily LTRA</title>
          <description>Daily leukotriene receptor antagonist (LTRA) treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Simple laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Penumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>asthma exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="300"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>tonsilitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="300"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="300"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="212" subjects_at_risk="300"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="300"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="300"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="300"/>
                <counts group_id="E3" events="29" subjects_affected="28" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="127" subjects_affected="100" subjects_at_risk="300"/>
                <counts group_id="E2" events="111" subjects_affected="89" subjects_at_risk="300"/>
                <counts group_id="E3" events="146" subjects_affected="109" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="300"/>
                <counts group_id="E3" events="17" subjects_affected="11" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="45" subjects_affected="39" subjects_at_risk="300"/>
                <counts group_id="E2" events="53" subjects_affected="41" subjects_at_risk="300"/>
                <counts group_id="E3" events="65" subjects_affected="54" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="300"/>
                <counts group_id="E2" events="21" subjects_affected="16" subjects_at_risk="300"/>
                <counts group_id="E3" events="36" subjects_affected="26" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="300"/>
                <counts group_id="E2" events="42" subjects_affected="35" subjects_at_risk="300"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="300"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="300"/>
                <counts group_id="E2" events="70" subjects_affected="59" subjects_at_risk="300"/>
                <counts group_id="E3" events="84" subjects_affected="68" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Mauger, PhD</name_or_title>
      <organization>Penn State University Dept of Public Health Sciences</organization>
      <phone>717.573.0336</phone>
      <email>dmauger@psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

